Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.66 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.66 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.64 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10341502 | 0.89 | ITGB3 (0.59) | ITGB3ITGA2BDGAT1BAZ2BNPC1 | |
| Phenethylamine SCHEMBL10944850 | 0.89 | DGAT1 (0.57) | ITGB3ITGA2BDGAT1BAZ2BNPC1 | |
| SCHEMBL10752862 | 0.89 | DGAT1 (0.57) | ITGB3ITGA2BDGAT1BAZ2BNPC1 | |
| SCHEMBL10752873 | 0.89 | DGAT1 (0.57) | ITGB3ITGA2BDGAT1BAZ2BNPC1 | |
| SCHEMBL14454770 | 0.88 | ITGB3 (0.53) | ITGB3ITGA2BDGAT1BAZ2BNPC1 | |
| SCHEMBL10750981 | 0.87 | ITGB3 (0.51) | ITGB3ITGA2BDGAT1BAZ2BNPC1 | |
| SCHEMBL5582711 | 0.84 | BAZ2B (0.52) | ITGB3ITGA2BDGAT1BAZ2BNPC1 | |
| SCHEMBL10341504 | 0.83 | BAZ2B (0.51) | ITGB3ITGA2BDGAT1BAZ2BNPC1 | |
| SCHEMBL5582919 | 0.81 | BAZ2B (0.52) | ITGB3ITGA2BBAZ2BNPC1RAB9A | |
| SCHEMBL7220756 | 0.81 | MTNR1A (0.69) | ITGB3ITGA2BDGAT1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
| US-4692447-A | HYPOTENSIVE, VASODILATOR, ANTITHROMBOTIC, ANTIAGGREGANT, CYTOPROTECTIVE | BOEHRINGER BIOCHEMIA ROBIN, S.P.A. (IT) | 1987-09-08 | — | — | US | disclosed |
| EP-0169443-A2 | Tricyclic dihydropyridazinones and pharmaceutical compositions contaning them | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1986-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | ITGB3 4150/4885ITGA2B 4209/4885DGAT1 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.